Stefan Gross serves as the Chief Scientific Officer at Arpeggio Biosciences since December 2025, bringing extensive experience in the biotechnology and pharmaceutical industries. Previously, Stefan was Vice President of Biology at Enliven Therapeutics and held senior positions at Pfizer and Array BioPharma Inc., overseeing significant drug discovery and development programs. Notable achievements include leading immuno-oncology initiatives and managing various oncology drug discovery projects. At Blueprint Medicines, Stefan directed efforts in small molecule inhibitors targeting novel kinase pathways. With a PhD in Cell and Molecular Biology from the University of Wisconsin-Madison and a BA in Molecular, Cellular and Developmental Biology from the University of Colorado, Stefan has demonstrated a strong academic foundation alongside a robust professional track record in scientific research and drug development.
This person is not in any teams
This person is not in any offices